lamivudine and zidovudine (71335-1916)

Drug Facts

Product Profile

Brand Name lamivudine and zidovudine

Generic Name lamivudine and zidovudine

Labeler bryant ranch prepack

Dosage Form TABLET

Routes

ORAL

Active Ingredients

lamivudine 150 mg/1, zidovudine 300 mg/1

Manufacturer

Bryant Ranch Prepack

Identifiers & Regulatory

Product NDC 71335-1916

Product ID 71335-1916_ae1913db-ec19-4f19-9ca8-0c524410de4c

Product Type HUMAN PRESCRIPTION DRUG

Marketing Category ANDA

Application Number ANDA090679

Listing Expiration 2026-12-31

Marketing Start 2018-08-30

Pharmacologic Class

Established (EPC)

hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc] human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]

Mechanism of Action

nucleoside reverse transcriptase inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 713351916

Hyphenated Format 71335-1916

Supplemental Identifiers

RxCUI

200082

UNII

2T8Q726O95 4B9XT59T7S

NUI

N0000175656 N0000175462 N0000009947

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name lamivudine and zidovudine (source: ndc)

Generic Name lamivudine and zidovudine (source: ndc)

Application Number ANDA090679 (source: ndc)

Routes

ORAL

source: ndc

Resolved Composition

Strengths

150 mg/1
300 mg/1

source: ndc

Packaging

6 TABLET in 1 BOTTLE (71335-1916-1)
60 TABLET in 1 BOTTLE (71335-1916-2)
4 TABLET in 1 BOTTLE (71335-1916-3)

source: ndc

Packages (3)

71335-1916-1 6 TABLET in 1 BOTTLE (71335-1916-1) 71335-1916-2 60 TABLET in 1 BOTTLE (71335-1916-2) 71335-1916-3 4 TABLET in 1 BOTTLE (71335-1916-3)

Ingredients (2)

lamivudine (150 mg/1) zidovudine (300 mg/1)

Linked Drug Pages (1)

Lamivudine and Zidovudine ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload

{"route": ["ORAL"], "spl_id": "ae1913db-ec19-4f19-9ca8-0c524410de4c", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "unii": ["2T8Q726O95", "4B9XT59T7S"], "rxcui": ["200082"], "spl_set_id": ["61d14a88-9fdf-4373-8360-44ec9e1cd350"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Bryant Ranch Prepack"]}, "finished": true, "packaging": [{"sample": false, "description": "6 TABLET in 1 BOTTLE (71335-1916-1)", "package_ndc": "71335-1916-1", "marketing_start_date": "20210715"}, {"sample": false, "description": "60 TABLET in 1 BOTTLE (71335-1916-2)", "package_ndc": "71335-1916-2", "marketing_start_date": "20240405"}, {"sample": false, "description": "4 TABLET in 1 BOTTLE (71335-1916-3)", "package_ndc": "71335-1916-3", "marketing_start_date": "20240405"}], "brand_name": "Lamivudine and Zidovudine", "product_id": "71335-1916_ae1913db-ec19-4f19-9ca8-0c524410de4c", "dosage_form": "TABLET", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "71335-1916", "generic_name": "Lamivudine and Zidovudine", "labeler_name": "Bryant Ranch Prepack", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Lamivudine and Zidovudine", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}, {"name": "ZIDOVUDINE", "strength": "300 mg/1"}], "application_number": "ANDA090679", "marketing_category": "ANDA", "marketing_start_date": "20180830", "listing_expiration_date": "20261231"}